{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:40:53Z","timestamp":1761093653327,"version":"build-2065373602"},"reference-count":3,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.bcmd.2009.12.001","type":"journal-article","created":{"date-parts":[[2009,12,23]],"date-time":"2009-12-23T05:29:39Z","timestamp":1261546179000},"page":"84-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Recommendations for treating patients with Gaucher disease with emerging enzyme products"],"prefix":"10.1016","volume":"44","author":[{"given":"Timothy M.","family":"Cox","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2009.12.001_bib1","unstructured":"European Medicines Agency (EMEA). Questions and answers on the shortages of Cerezyme and Fabrazyme. 14-8-2009."},{"key":"10.1016\/j.bcmd.2009.12.001_bib2","article-title":"Force Majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease","author":"Hollak","year":"2009","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2009.12.001_bib3","unstructured":"European Medicines Agency (EMEA) Updated temporary treatment recommendations for Cerezyme. Doc. Ref. EMEA\/665112\/2009 22-10-2009."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979609002186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979609002186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:25:53Z","timestamp":1761049553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979609002186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":3,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S1079979609002186"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2009.12.001","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations for treating patients with Gaucher disease with emerging enzyme products","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2009.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2009 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}